首页 > 最新文献

Respiration最新文献

英文 中文
Novel Insights from Clinical Practice Autologous Blood Patch Pleurodesis and Endobronchial Valves for Management of Persistent Air Leaks in Two Cases of Tuberculosis. 自体血补片胸膜穿刺术和支气管内瓣膜用于治疗两例肺结核持续漏气。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-02-28 DOI: 10.1159/000537992
Aida F Martinez, Zachary Tom, David W Hsia, Janine Vintch, Nathan Yee

Introduction: Pulmonary infections, such as tuberculosis, can result in numerous pleural complications including empyemas, pneumothoraces with broncho-pleural fistulas, and persistent air leak (PAL). While definitive surgical interventions are often initially considered, management of these complications can be particularly challenging if a patient has an active infection and is not a surgical candidate.

Case presentation: Autologous blood patch pleurodesis and endobronchial valve placement have both been described in remedying PALs effectively and safely. PALs due to broncho-pleural fistulas in active pulmonary disease are rare, and we present two such cases that were managed with autologous blood patch pleurodesis and endobronchial valves.

Conclusion: The two cases presented illustrate the complexities of PAL management and discuss the treatment options that can be applied to individual patients.

肺部感染(如肺结核)可导致多种胸膜并发症,包括气胸、气胸伴支气管胸膜瘘和持续性漏气。虽然一开始通常会考虑采取明确的手术干预措施,但如果患者的感染处于活动期且不适合手术治疗,这些并发症的处理就会特别具有挑战性。自体血补片胸膜穿刺术和支气管内瓣膜置入术均可有效、安全地补救持续性气漏(PALs)。活动性肺病支气管胸膜瘘导致的持续性气漏非常罕见,我们介绍了两例采用自体血补片胸膜穿刺术和支气管内瓣膜置入术治疗的病例。
{"title":"Novel Insights from Clinical Practice Autologous Blood Patch Pleurodesis and Endobronchial Valves for Management of Persistent Air Leaks in Two Cases of Tuberculosis.","authors":"Aida F Martinez, Zachary Tom, David W Hsia, Janine Vintch, Nathan Yee","doi":"10.1159/000537992","DOIUrl":"10.1159/000537992","url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary infections, such as tuberculosis, can result in numerous pleural complications including empyemas, pneumothoraces with broncho-pleural fistulas, and persistent air leak (PAL). While definitive surgical interventions are often initially considered, management of these complications can be particularly challenging if a patient has an active infection and is not a surgical candidate.</p><p><strong>Case presentation: </strong>Autologous blood patch pleurodesis and endobronchial valve placement have both been described in remedying PALs effectively and safely. PALs due to broncho-pleural fistulas in active pulmonary disease are rare, and we present two such cases that were managed with autologous blood patch pleurodesis and endobronchial valves.</p><p><strong>Conclusion: </strong>The two cases presented illustrate the complexities of PAL management and discuss the treatment options that can be applied to individual patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"289-294"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association between Objectively Measured Physical Activity and the Prevalence of Comorbidities in Lung Transplant Recipients. 肺移植受者客观测量的体力活动量与合并症患病率之间的关系。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-03-08 DOI: 10.1159/000536607
Sofie Breuls, Astrid Blondeel, Marieke Wuyts, Geert M Verleden, Robin Vos, Wim Janssens, Thierry Troosters, Heleen Demeyer

Introduction: Lung transplant recipients are often physically inactive and are at risk of developing comorbidities. We investigated whether objectively measured physical activity was associated with the prevalence of comorbidities.

Methods: Physical activity (accelerometry) and the presence of cardiovascular disease, symptoms of depression and anxiety, diabetes, dyslipidaemia, hypertension, lower extremity artery disease, muscle weakness, obesity, and osteoporosis were assessed in 108 lung transplant recipients. Patients were divided into four groups based on daily step count.

Results: A cohort of 108 patients (60 ± 7 years, 51% male, 20 ± 14 months since transplantation) was included. Active patients (>7,500 steps/day) had significantly fewer comorbidities (4 comorbidities) compared to severely inactive patients (<2,500 steps/day, 6 comorbidities), and muscle weakness and high symptoms of depression were less prevalent. Severely inactive patients had significantly more cardiovascular comorbidities compared to all other groups. No other significant differences were observed.

Conclusion: Physically active lung transplant recipients have fewer comorbidities, lower prevalence of muscle weakness, and fewer symptoms of depression compared to very inactive patients.

导言:肺移植受者通常缺乏体育锻炼,有患合并症的风险。我们研究了客观测量的体力活动是否与合并症的发生率有关。方法 我们对 108 名肺移植受者的体力活动(加速度计)以及是否患有心血管疾病、抑郁和焦虑症状、糖尿病、血脂异常、高血压、下肢动脉疾病、肌无力、肥胖和骨质疏松症进行了评估。根据每日步数将患者分为四组。结果 共纳入 108 名患者(60±7 岁,51% 为男性,移植后 20±14 个月)。与严重缺乏运动的患者(60±7 岁,51% 为男性,移植后 20±14 个月)相比,运动活跃的患者(每天大于 7500 步)的合并症(4 种合并症)明显较少。
{"title":"The Association between Objectively Measured Physical Activity and the Prevalence of Comorbidities in Lung Transplant Recipients.","authors":"Sofie Breuls, Astrid Blondeel, Marieke Wuyts, Geert M Verleden, Robin Vos, Wim Janssens, Thierry Troosters, Heleen Demeyer","doi":"10.1159/000536607","DOIUrl":"10.1159/000536607","url":null,"abstract":"<p><strong>Introduction: </strong>Lung transplant recipients are often physically inactive and are at risk of developing comorbidities. We investigated whether objectively measured physical activity was associated with the prevalence of comorbidities.</p><p><strong>Methods: </strong>Physical activity (accelerometry) and the presence of cardiovascular disease, symptoms of depression and anxiety, diabetes, dyslipidaemia, hypertension, lower extremity artery disease, muscle weakness, obesity, and osteoporosis were assessed in 108 lung transplant recipients. Patients were divided into four groups based on daily step count.</p><p><strong>Results: </strong>A cohort of 108 patients (60 ± 7 years, 51% male, 20 ± 14 months since transplantation) was included. Active patients (&gt;7,500 steps/day) had significantly fewer comorbidities (4 comorbidities) compared to severely inactive patients (&lt;2,500 steps/day, 6 comorbidities), and muscle weakness and high symptoms of depression were less prevalent. Severely inactive patients had significantly more cardiovascular comorbidities compared to all other groups. No other significant differences were observed.</p><p><strong>Conclusion: </strong>Physically active lung transplant recipients have fewer comorbidities, lower prevalence of muscle weakness, and fewer symptoms of depression compared to very inactive patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"251-256"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence Algorithm Can Predict Lymph Node Malignancy from Endobronchial Ultrasound Transbronchial Needle Aspiration Images for Non-Small Cell Lung Cancer. 人工智能算法可从EBUS-TBNA图像预测NSCLC淋巴结恶性程度
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-09-14 DOI: 10.1159/000541365
Yogita S Patel, Anthony A Gatti, Forough Farrokhyar, Feng Xie, Waël C Hanna

Introduction: Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) for lung cancer staging is operator dependent, resulting in high rates of non-diagnostic lymph node (LN) samples. We hypothesized that an artificial intelligence (AI) algorithm can consistently and reliably predict nodal metastases from the ultrasound images of LNs when compared to pathology.

Methods: In this analysis of prospectively recorded B-mode images of mediastinal LNs during EBUS-TBNA, we used transfer learning to build an end-to-end ensemble of three deep neural networks (ResNet152V2, InceptionV3, and DenseNet201). Model hyperparameters were tuned, and the optimal version(s) of each model was trained using 80% of the images. A learned ensemble (multi-layer perceptron) of the optimal versions was applied to the remaining 20% of the images (Test Set). All predictions were compared to the final pathology from nodal biopsies and/or surgical specimen.

Results: A total of 2,569 LN images from 773 patients were used. The Training Set included 2,048 LNs, of which 70.02% were benign and 29.98% were malignant on pathology. The Testing Set included 521 LNs, of which 70.06% were benign and 29.94% were malignant on pathology. The final ensemble model had an overall accuracy of 80.63% (95% confidence interval [CI]: 76.93-83.97%), 43.23% sensitivity (95% CI: 35.30-51.41%), 96.91% specificity (95% CI: 94.54-98.45%), 85.90% positive predictive value (95% CI: 76.81-91.80%), 79.68% negative predictive value (95% CI: 77.34-81.83%), and AUC of 0.701 (95% CI: 0.646-0.755) for malignancy.

Conclusion: There now exists an AI algorithm which can identify nodal metastases based only on ultrasound images with good overall accuracy, specificity, and positive predictive value. Further optimization with larger sample sizes would be beneficial prior to clinical application.

简介:用于肺癌分期的EBUS-TBNA取决于操作者,导致淋巴结(LN)样本的非诊断率很高。我们假设,与病理学相比,人工智能(AI)算法可以通过淋巴结的超声图像持续、可靠地预测淋巴结转移:在对 EBUS-TBNA 过程中前瞻性记录的纵隔 LN B 型图像进行分析时,我们使用迁移学习建立了由三个深度神经网络(ResNet152V2、InceptionV3 和 DenseNet201)组成的端到端集合。对模型超参数进行调整,并使用 80% 的图像对每个模型的最佳版本进行训练。最优版本的学习集合(多层感知器)被应用于剩余的 20% 图像(测试集)。所有预测结果都与结节活检和/或手术标本的最终病理结果进行了比较:共使用了来自 773 名患者的 2,569 张 LN 图像。训练集包括 2,048 个 LN,其中 70.02% 为良性,29.98% 为病理恶性。测试集包括 521 个 LN,其中 70.06% 为良性,29.94% 为病理恶性。最终组合模型的总体准确率为 80.63% [95%置信区间 (CI):76.93%-83.97%],灵敏度为 43.23%(95%CI:35.30%-51.41%),特异性为 96.91%(95%CI:94.54%-98.45%),阳性率为 85.90%。45%),阳性预测值为 85.90%(95%CI:76.81%-91.80%),阴性预测值为 79.68%(95%CI:77.34%-81.83%),恶性肿瘤的 AUC 为 0.701(95%CI:0.646-0.755):目前已有一种人工智能算法,它能仅根据超声图像识别结节转移,并具有良好的总体准确性、特异性和阳性预测值。在临床应用之前,进一步优化更大的样本量将是有益的。
{"title":"Artificial Intelligence Algorithm Can Predict Lymph Node Malignancy from Endobronchial Ultrasound Transbronchial Needle Aspiration Images for Non-Small Cell Lung Cancer.","authors":"Yogita S Patel, Anthony A Gatti, Forough Farrokhyar, Feng Xie, Waël C Hanna","doi":"10.1159/000541365","DOIUrl":"10.1159/000541365","url":null,"abstract":"<p><strong>Introduction: </strong>Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) for lung cancer staging is operator dependent, resulting in high rates of non-diagnostic lymph node (LN) samples. We hypothesized that an artificial intelligence (AI) algorithm can consistently and reliably predict nodal metastases from the ultrasound images of LNs when compared to pathology.</p><p><strong>Methods: </strong>In this analysis of prospectively recorded B-mode images of mediastinal LNs during EBUS-TBNA, we used transfer learning to build an end-to-end ensemble of three deep neural networks (ResNet152V2, InceptionV3, and DenseNet201). Model hyperparameters were tuned, and the optimal version(s) of each model was trained using 80% of the images. A learned ensemble (multi-layer perceptron) of the optimal versions was applied to the remaining 20% of the images (Test Set). All predictions were compared to the final pathology from nodal biopsies and/or surgical specimen.</p><p><strong>Results: </strong>A total of 2,569 LN images from 773 patients were used. The Training Set included 2,048 LNs, of which 70.02% were benign and 29.98% were malignant on pathology. The Testing Set included 521 LNs, of which 70.06% were benign and 29.94% were malignant on pathology. The final ensemble model had an overall accuracy of 80.63% (95% confidence interval [CI]: 76.93-83.97%), 43.23% sensitivity (95% CI: 35.30-51.41%), 96.91% specificity (95% CI: 94.54-98.45%), 85.90% positive predictive value (95% CI: 76.81-91.80%), 79.68% negative predictive value (95% CI: 77.34-81.83%), and AUC of 0.701 (95% CI: 0.646-0.755) for malignancy.</p><p><strong>Conclusion: </strong>There now exists an AI algorithm which can identify nodal metastases based only on ultrasound images with good overall accuracy, specificity, and positive predictive value. Further optimization with larger sample sizes would be beneficial prior to clinical application.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"741-751"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 after 2 Years from Hospital Discharge: A Pulmonary Function and Chest Computed Tomography Follow-Up Study. 出院两年后的 COVID-19:肺功能和胸部计算机断层扫描随访研究
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-01-09 DOI: 10.1159/000535732
Simone Mennella, Cristiano Alicino, Marco Anselmo, Giuliana Carrega, Gianluca Ficarra, Luca Garra, Alessandro Gastaldo, Paola Gnerre, Flavia Lillo, Rodolfo Tassara, Anna Terrile, Manlio Milanese

Introduction: Serial follow-up with pulmonary function testing (PFT) and chest computed tomography (CT) after severe COVID-19 are recommended. As a result, many longitudinal studies have been published on COVID-19 of different grade of severity up to 1-year follow-up. Therefore, we aimed at a long-term observational study throughout 2 years after severe COVID-19.

Methods: Severe COVID-19 patients were consecutively recruited after hospital discharge between March and June 2020 and prospectively followed up for 24 months, with mMRC dyspnea scale and PFT at 6, 12, and 24 months. Chest CT was performed when clinically indicated.

Results: One hundred one patients enrolled completed the observational study. At 24 months, those with reduced total lung capacity (TLC) were 16%, associated with fibrotic ground glass opacity (GGO) and mMRC score >1, respectively, in 75% and 69% of them. At 24 months, those with a reduced diffusing capacity of the lung for CO were 41%, associated with fibrotic GGO and mMRC score >1, respectively, in 53% and 22% of them.

Conclusion: Two years after hospitalization for severe COVID-19, a non-negligible number of patients still suffer from "long COVID" due to respiratory damage.

简介:建议在严重的 COVID-19 后通过肺功能测试(PFT)和胸部计算机断层扫描(CT)进行连续随访。因此,许多关于不同严重程度的 COVID-19 的纵向研究已发表至 1 年随访。因此,我们旨在对重症 COVID-19 患者进行为期 2 年的长期观察研究:方法:在 2020 年 3 月至 6 月期间,连续招募出院后的重度 COVID-19 患者,对其进行为期 24 个月的前瞻性随访,并在 6、12 和 24 个月时进行 mMRC 呼吸困难量表和 PFT 检查。有临床指征时进行胸部 CT 检查:结果:1001 名患者完成了观察性研究。24 个月时,总肺活量(TLC)降低的患者占 16%,其中 75% 和 69% 的患者分别伴有纤维化磨玻璃不透明(GGO)和 mMRC 评分 1。24个月时,肺部对一氧化碳的弥散能力降低的患者占41%,其中53%和22%的患者分别伴有纤维化的GGO和mMRC评分>1:结论:重症 COVID-19 患者住院两年后,仍有相当数量的患者因呼吸系统损伤而患有 "长期 COVID"。
{"title":"COVID-19 after 2 Years from Hospital Discharge: A Pulmonary Function and Chest Computed Tomography Follow-Up Study.","authors":"Simone Mennella, Cristiano Alicino, Marco Anselmo, Giuliana Carrega, Gianluca Ficarra, Luca Garra, Alessandro Gastaldo, Paola Gnerre, Flavia Lillo, Rodolfo Tassara, Anna Terrile, Manlio Milanese","doi":"10.1159/000535732","DOIUrl":"10.1159/000535732","url":null,"abstract":"<p><strong>Introduction: </strong>Serial follow-up with pulmonary function testing (PFT) and chest computed tomography (CT) after severe COVID-19 are recommended. As a result, many longitudinal studies have been published on COVID-19 of different grade of severity up to 1-year follow-up. Therefore, we aimed at a long-term observational study throughout 2 years after severe COVID-19.</p><p><strong>Methods: </strong>Severe COVID-19 patients were consecutively recruited after hospital discharge between March and June 2020 and prospectively followed up for 24 months, with mMRC dyspnea scale and PFT at 6, 12, and 24 months. Chest CT was performed when clinically indicated.</p><p><strong>Results: </strong>One hundred one patients enrolled completed the observational study. At 24 months, those with reduced total lung capacity (TLC) were 16%, associated with fibrotic ground glass opacity (GGO) and mMRC score &gt;1, respectively, in 75% and 69% of them. At 24 months, those with a reduced diffusing capacity of the lung for CO were 41%, associated with fibrotic GGO and mMRC score &gt;1, respectively, in 53% and 22% of them.</p><p><strong>Conclusion: </strong>Two years after hospitalization for severe COVID-19, a non-negligible number of patients still suffer from \"long COVID\" due to respiratory damage.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"22-31"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex Difference in Characteristics and Predictors of In-Hospital Mortality among Patients with COVID-19. COVID-19 患者住院死亡率的特征和预测因素的性别差异。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1159/000539281
Shirui Meng, Zechun Zeng, Huijuan Zuo, Jinwen Wang

Introduction: With a surge in the prevalence of coronavirus disease-2019 (COVID-19) in Beijing starting in October 2022, hospitalisation rates increased markedly. This study aimed to evaluate factors associated with in-hospital mortality in patients with COVID-19.

Methods: Using data from hospitalised patients, sex-based differences in clinical characteristics, in-hospital management, and in-hospital mortality among patients diagnosed with COVID-19 were evaluated. Predictive factors associated with mortality in 1,091 patients admitted to the Beijing Anzhen Hospital (Beijing, China) for COVID-19 between October 2022 and January 2023 were also evaluated.

Results: Data from 1,091 patients hospitalised with COVID-19 were included in the analysis. In-hospital mortality rates for male and female patients were 14.9% and 10.4%, respectively. Multifactorial logistic analysis indicated that lymphocyte percentage (LYM%) (odds ratio [OR] 0.863, 95% confidence interval [CI] 0.805-0.925; p < 0.001), uric acid (OR 1.004, 95% CI: 1.002-1.006; p = 0.001), and high-sensitivity C-reactive protein (OR 1.094, 95% CI: 1.012-1.183; p = 0.024) levels were independently associated with COVID-19-related in-hospital mortality. Among female patients, multifactorial analysis revealed that LYM% (OR 0.856, 95% CI: 0.796-0.920; p < 0.001), older age (OR 1.061, 95% CI: 1.020-1.103; p = 0.003), obesity (OR 2.590, 95% CI: 1.131-5.931; p = 0.024), and a high high-sensitivity troponin I level (OR 2.602, 95% CI: 1.157-5.853; p = 0.021) were risk factors for in-hospital mortality. Receiver operating characteristic (ROC) curve analysis, including area under the ROC curve, showed that the efficacy of LYM% in predicting in-hospital death was 0.800 (sensitivity, 63.2%; specificity, 83.2%) in male patients and 0.815 (sensitivity, 87.5%; specificity, 64.4%) in female patients.

Conclusion: LYM% is a consistent predictor of in-hospital mortality for both sexes. Older age and markers of systemic inflammation, myocardial injury, and metabolic dysregulation are also associated with a high mortality risk. These findings may help identify patients who require closer monitoring and tailored interventions to improve outcomes.

导言:自2022年10月起,随着冠状病毒病(COVID-19)在北京的流行,住院人数明显增加。本研究旨在评估与 COVID-19 患者院内死亡率相关的因素:方法:利用住院患者的数据,评估确诊为 COVID-19 的患者在临床特征、院内管理和院内死亡率方面的性别差异。此外,还对北京安贞医院(中国北京)在2022年10月至2023年1月期间收治的1091名COVID-19患者的死亡率相关预测因素进行了评估:分析纳入了1091名COVID-19住院患者的数据。男性和女性的院内死亡率分别为14.9%和10.4%。多因素逻辑分析显示,淋巴细胞百分比(LYM%)(几率比[OR] 0.863 [95% 置信区间(CI)0.805-0.925];P<0.001)、尿酸(OR 1.004 [95% CI 1.002-1.006];P=0.001)和高敏C反应蛋白(hs-CRP)(OR 1.094 [95% CI 1.012-1.183];P=0.024)与COVID-19的院内死亡率独立相关。在女性患者中,多因素分析显示,LYM%(OR 0.856 [95% CI 0.796-0.920];P<0.001)、年龄较大(OR 1.061 [95% CI 1.020-1.103];P=0.003)、肥胖(OR 2.590[95%CI1.131-5.931];P=0.024)、高敏肌钙蛋白 I 水平高(OR 2.602[95%CI 1.157-5.853];P=0.021)是院内死亡的危险因素。接收者操作特征(ROC)曲线分析显示,LYM%在预测男性院内死亡方面的有效性及其ROC曲线下面积(AUC)为0.800,敏感性为63.2%,特异性为83.2%。预测女性住院死亡的 AUC 为 0.815,灵敏度为 87.5%,特异度为 64.4%:结论:LYM%是预测男女住院死亡率的一致指标。结论:LYM%是男女患者院内死亡率的一致预测指标,年龄越大,全身炎症、心肌损伤和代谢失调的标记物越多,死亡率越高。这些发现有助于确定哪些患者需要更密切的监测和有针对性的干预,以改善预后。
{"title":"Sex Difference in Characteristics and Predictors of In-Hospital Mortality among Patients with COVID-19.","authors":"Shirui Meng, Zechun Zeng, Huijuan Zuo, Jinwen Wang","doi":"10.1159/000539281","DOIUrl":"10.1159/000539281","url":null,"abstract":"<p><strong>Introduction: </strong>With a surge in the prevalence of coronavirus disease-2019 (COVID-19) in Beijing starting in October 2022, hospitalisation rates increased markedly. This study aimed to evaluate factors associated with in-hospital mortality in patients with COVID-19.</p><p><strong>Methods: </strong>Using data from hospitalised patients, sex-based differences in clinical characteristics, in-hospital management, and in-hospital mortality among patients diagnosed with COVID-19 were evaluated. Predictive factors associated with mortality in 1,091 patients admitted to the Beijing Anzhen Hospital (Beijing, China) for COVID-19 between October 2022 and January 2023 were also evaluated.</p><p><strong>Results: </strong>Data from 1,091 patients hospitalised with COVID-19 were included in the analysis. In-hospital mortality rates for male and female patients were 14.9% and 10.4%, respectively. Multifactorial logistic analysis indicated that lymphocyte percentage (LYM%) (odds ratio [OR] 0.863, 95% confidence interval [CI] 0.805-0.925; p &lt; 0.001), uric acid (OR 1.004, 95% CI: 1.002-1.006; p = 0.001), and high-sensitivity C-reactive protein (OR 1.094, 95% CI: 1.012-1.183; p = 0.024) levels were independently associated with COVID-19-related in-hospital mortality. Among female patients, multifactorial analysis revealed that LYM% (OR 0.856, 95% CI: 0.796-0.920; p &lt; 0.001), older age (OR 1.061, 95% CI: 1.020-1.103; p = 0.003), obesity (OR 2.590, 95% CI: 1.131-5.931; p = 0.024), and a high high-sensitivity troponin I level (OR 2.602, 95% CI: 1.157-5.853; p = 0.021) were risk factors for in-hospital mortality. Receiver operating characteristic (ROC) curve analysis, including area under the ROC curve, showed that the efficacy of LYM% in predicting in-hospital death was 0.800 (sensitivity, 63.2%; specificity, 83.2%) in male patients and 0.815 (sensitivity, 87.5%; specificity, 64.4%) in female patients.</p><p><strong>Conclusion: </strong>LYM% is a consistent predictor of in-hospital mortality for both sexes. Older age and markers of systemic inflammation, myocardial injury, and metabolic dysregulation are also associated with a high mortality risk. These findings may help identify patients who require closer monitoring and tailored interventions to improve outcomes.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"480-487"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endobronchial Valves in Treatment of Persistent Air Leak: European Case-Series Study and Best Practice Recommendations - From an Expert Panel. 治疗持续性漏气的支气管内瓣膜:欧洲病例系列研究和最佳实践建议 - 来自专家小组。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-06-13 DOI: 10.1159/000539573
Illaa Smesseim, Louis-Vincent Morin-Thibault, Felix J F Herth, James Tonkin, Pallav L Shah, Dirk-Jan Slebos, David T Koster, Chris Dickhoff, Johannes Marlene Andreas Daniels, Jouke Annema, Peter Bonta

Introduction: Persistent air leak (PAL) is associated with prolonged hospitalization, high morbidity and increased treatment costs. Conservative treatment consists of observation, chest tube drainage, and pleurodesis. Guidelines recommend surgical evaluation if air leak does not respond after 3-5 days. One-way endobronchial valves (EBV) have been proposed as a treatment option for patients with PAL in which surgical treatment is not feasible, high risk or has failed. We aimed to provide a comprehensive overview of reported EBV use for PAL and issue best practice recommendations based on multicenter experience.

Methods: We conducted a retrospective observational case-series study at four different European academic hospitals and provided best practice recommendations based on our experience. A systematic literature review was performed to summarize the current knowledge on EBV in PAL.

Results: We enrolled 66 patients, male (66.7%), median age 59.5 years. The most common underlying lung disease was chronic obstructive pulmonary disease (39.4%) and lung cancer (33.3%). The median time between pneumothorax and valve placement was 24.5 days (interquartile range: 14.0-54.3). Air leak resolved in 40/66 patients (60.6%) within 30 days after EBV treatment. Concerning safety outcome, no procedure-related mortality was reported and complication rate was low (6.1%). Five patients (7.6%) died in the first 30 days after intervention.

Conclusion: EBV placement is a treatment option in patients with PAL. In this multicenter case-series of high-risk patients not eligible for lung surgery, we show that EBV placement resulted in air leak resolution in 6 out of 10 patients with a low complication rate. Considering the minimally invasive nature of EBV to treat PAL as opposed to surgery, further research should investigate if EBV treatment should be expanded in low to intermediate risk PAL patients.

导言:持续性气漏(PAL)与住院时间长、发病率高和治疗费用增加有关。保守治疗包括观察、胸腔管引流和胸膜穿刺术。如果气漏在 3-5 天后仍无反应,指南建议进行手术评估。单向支气管内瓣膜(EBV)已被提议作为一种治疗方案,用于手术治疗不可行、高风险或失败的 PAL 患者。我们的目的是全面概述 EBV 用于 PAL 的报道,并根据多中心经验提出最佳实践建议。方法 我们在四家不同的欧洲学术医院开展了一项回顾性观察病例系列研究,并根据我们的经验提出了最佳实践建议。我们还进行了系统的文献综述,总结了目前有关 PAL 中 EBV 的知识。结果 我们共招募了 66 名患者,男性(66.7%),中位年龄为 59.5 岁。最常见的肺部疾病是慢性阻塞性肺病(39.4%)和肺癌(33.3%)。气胸与瓣膜置入之间的中位时间为 24.5 天(IQR:14.0-54.3)。40/66的患者(60.6%)在接受支气管内瓣膜治疗后30天内解决了漏气问题。在安全性方面,没有与手术相关的死亡率报告,并发症发生率较低(6.1%)。5 名患者(7.6%)在介入治疗后 30 天内死亡。结论 EBV 置入术是治疗持续性气漏 (PAL) 患者的一种选择。在这一多中心病例系列中,我们对不符合肺部手术条件的高风险患者进行了研究,结果显示,10 名患者中有 6 名通过 EBV 置入术解决了气漏问题,且并发症发生率较低。考虑到 EBV 治疗 PAL 的微创性优于手术,进一步的研究应探讨是否应将 EBV 治疗扩大到中低风险的 PAL 患者。
{"title":"Endobronchial Valves in Treatment of Persistent Air Leak: European Case-Series Study and Best Practice Recommendations - From an Expert Panel.","authors":"Illaa Smesseim, Louis-Vincent Morin-Thibault, Felix J F Herth, James Tonkin, Pallav L Shah, Dirk-Jan Slebos, David T Koster, Chris Dickhoff, Johannes Marlene Andreas Daniels, Jouke Annema, Peter Bonta","doi":"10.1159/000539573","DOIUrl":"10.1159/000539573","url":null,"abstract":"<p><strong>Introduction: </strong>Persistent air leak (PAL) is associated with prolonged hospitalization, high morbidity and increased treatment costs. Conservative treatment consists of observation, chest tube drainage, and pleurodesis. Guidelines recommend surgical evaluation if air leak does not respond after 3-5 days. One-way endobronchial valves (EBV) have been proposed as a treatment option for patients with PAL in which surgical treatment is not feasible, high risk or has failed. We aimed to provide a comprehensive overview of reported EBV use for PAL and issue best practice recommendations based on multicenter experience.</p><p><strong>Methods: </strong>We conducted a retrospective observational case-series study at four different European academic hospitals and provided best practice recommendations based on our experience. A systematic literature review was performed to summarize the current knowledge on EBV in PAL.</p><p><strong>Results: </strong>We enrolled 66 patients, male (66.7%), median age 59.5 years. The most common underlying lung disease was chronic obstructive pulmonary disease (39.4%) and lung cancer (33.3%). The median time between pneumothorax and valve placement was 24.5 days (interquartile range: 14.0-54.3). Air leak resolved in 40/66 patients (60.6%) within 30 days after EBV treatment. Concerning safety outcome, no procedure-related mortality was reported and complication rate was low (6.1%). Five patients (7.6%) died in the first 30 days after intervention.</p><p><strong>Conclusion: </strong>EBV placement is a treatment option in patients with PAL. In this multicenter case-series of high-risk patients not eligible for lung surgery, we show that EBV placement resulted in air leak resolution in 6 out of 10 patients with a low complication rate. Considering the minimally invasive nature of EBV to treat PAL as opposed to surgery, further research should investigate if EBV treatment should be expanded in low to intermediate risk PAL patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"544-562"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous Ultrasound-Guided Medication Injection: A Potential Technique for Subglottic Stenosis. 经皮超声引导药物注射,一种治疗声门下狭窄的潜在技术。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-06-27 DOI: 10.1159/000539974
Mingming Deng, Run Tong, Jieru Lin, Yiding Bian, Guowu Zhou, Felix J F Herth, Gang Hou

Introduction: Subglottic stenosis, manifested by granulation tissue hyperplasia, is challenging and requires multiple repeated treatments and stent maintenance at times. Corticosteroids prevent severe subglottic stenosis development owing to their antifibrotic and anti-inflammatory properties. Submucosal injection of glucocorticoids, a useful adjuvant therapeutic method, improves the mean interval between endoscopic procedures and reduces airway restenosis risks.

Case presentation: We report a rare case of a man with complex subglottic stenosis who underwent balloon dilatation combined with cryotherapy, stent placement, and adjuvant submucosal triamcinolone injection. The drug was injected efficiently and safely into the submucosal layer under percutaneous ultrasound guidance, and subglottic stenosis was well-controlled at a low cost.

Conclusion: POCUS-guided medication injections may be a useful adjuvant medical therapy for subglottic stenosis.

简介声门下狭窄表现为肉芽组织增生,具有挑战性,有时需要多次重复治疗和支架维护。皮质类固醇具有抗纤维化和抗炎特性,可预防严重声门下狭窄的发生。粘膜下注射糖皮质激素或丝裂霉素是一种有效的辅助治疗方法,可缩短内镜手术的平均间隔时间,降低气道再狭窄的风险:我们报告了一例罕见的复杂声门下狭窄男性患者的病例,该患者接受了球囊扩张联合冷冻治疗、支架置入和粘膜下曲安奈德注射辅助治疗。在经皮超声引导下,药物被高效、安全地注射到黏膜下层,声门下狭窄得到了很好的控制,且费用低廉:结论:POCUS 引导下的药物注射可能是治疗声门下狭窄的有效辅助医疗手段。
{"title":"Percutaneous Ultrasound-Guided Medication Injection: A Potential Technique for Subglottic Stenosis.","authors":"Mingming Deng, Run Tong, Jieru Lin, Yiding Bian, Guowu Zhou, Felix J F Herth, Gang Hou","doi":"10.1159/000539974","DOIUrl":"10.1159/000539974","url":null,"abstract":"<p><strong>Introduction: </strong>Subglottic stenosis, manifested by granulation tissue hyperplasia, is challenging and requires multiple repeated treatments and stent maintenance at times. Corticosteroids prevent severe subglottic stenosis development owing to their antifibrotic and anti-inflammatory properties. Submucosal injection of glucocorticoids, a useful adjuvant therapeutic method, improves the mean interval between endoscopic procedures and reduces airway restenosis risks.</p><p><strong>Case presentation: </strong>We report a rare case of a man with complex subglottic stenosis who underwent balloon dilatation combined with cryotherapy, stent placement, and adjuvant submucosal triamcinolone injection. The drug was injected efficiently and safely into the submucosal layer under percutaneous ultrasound guidance, and subglottic stenosis was well-controlled at a low cost.</p><p><strong>Conclusion: </strong>POCUS-guided medication injections may be a useful adjuvant medical therapy for subglottic stenosis.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"583-586"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation. 接受肺康复治疗的后 COVID-19 患者对支气管扩张剂的反应。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-07-18 DOI: 10.1159/000540297
Simon Alexander Krooss, Isabel Klefenz, Michael Ott, Frank Klawonn, Daniela Leitl, Tessa Schneeberger, Inga Jarosch, Claus Franz Vogelmeier, Marek Lommatzsch, Rainer Gloeckl, Andreas Rembert Koczulla

Introduction: SARS-CoV-2 infections can result in a broad spectrum of symptoms from mild to life-threatening. Long-term consequences on lung function are not well understood yet.

Methods: In our study, we have examined 134 post-COVID patients (aged 54.83 ± 14.4 years) with dyspnea on exertion as a leading symptom 6 weeks to 24 months after a SARS-CoV-2 infection for bronchodilator responsiveness during their stay in our pulmonary rehabilitation clinic.

Results: Prior to bronchial dilation, 6 out of 134 patients (4.47%) presented an FEV1/FVC ratio below lower limit of normal (Z-score = -1.645) indicative of an obstructive airway disease. Following inhalation of a β2-adrenergic agonist we measured a mean FEV1 increase of 181.5 mL in our cohort, which was significantly elevated compared to a historical control group (ΔFEV1 = 118 mL). 28.7% of the patients showed an increase greater than 200 mL and 12% displayed a significant bronchodilation response (>200 mL ΔFEV1 and >12% FEV1 increase). Interestingly, no significant difference in bronchial dilation effect was observed when comparing patients hospitalized and those non-hospitalized during the course of their SARS-CoV-2 infection.

Conclusion: Our data provide evidence for increased prevalence of obstructive ventilatory defects and increased bronchodilator responsiveness in patients with persisting symptoms after COVID-19. Depending on the extent of this complication, post-COVID patients may benefit from an adapted β2-inhalation therapy including subsequent reevaluation.

简介SARS-CoV-2 感染可导致从轻微到危及生命的各种症状。方法:我们研究了 134 名感染 SARS-CoV-2 后的患者(年龄为 54.83±14.4 岁):在我们的研究中,我们对 134 名以劳力性呼吸困难为主要症状的 SARS-CoV-2 感染后患者(年龄为 54.83±14.4 岁)在肺康复诊所住院 6 周至 24 个月期间的支气管扩张剂反应性进行了检查:在支气管扩张之前,134 名患者中有 6 人(4.47%)的 FEV1/FVC 比值低于正常下限(Z-score=-1.645),表明他们患有阻塞性气道疾病。吸入ß2-肾上腺素能激动剂后,我们测得组群的平均 FEV1 增加了 181.5 mL,与历史对照组(ΔFEV1 = 118 mL)相比显著增加。28.7% 的患者增加了 200 mL 以上,12% 的患者显示出明显的支气管扩张反应(>200 mL ΔFEV1 和>12% FEV1 增加)。有趣的是,在 SARS-CoV-2 感染期间,比较住院患者和非住院患者,没有观察到支气管扩张效果的明显差异:结论:我们的数据证明,在 COVID-19 后症状持续存在的患者中,阻塞性通气缺陷的发生率增加,支气管扩张剂的反应性增加。根据这种并发症的程度,COVID 后的患者可能会受益于经过调整的 ß2 吸入疗法,包括随后的重新评估。
{"title":"Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation.","authors":"Simon Alexander Krooss, Isabel Klefenz, Michael Ott, Frank Klawonn, Daniela Leitl, Tessa Schneeberger, Inga Jarosch, Claus Franz Vogelmeier, Marek Lommatzsch, Rainer Gloeckl, Andreas Rembert Koczulla","doi":"10.1159/000540297","DOIUrl":"10.1159/000540297","url":null,"abstract":"<p><strong>Introduction: </strong>SARS-CoV-2 infections can result in a broad spectrum of symptoms from mild to life-threatening. Long-term consequences on lung function are not well understood yet.</p><p><strong>Methods: </strong>In our study, we have examined 134 post-COVID patients (aged 54.83 ± 14.4 years) with dyspnea on exertion as a leading symptom 6 weeks to 24 months after a SARS-CoV-2 infection for bronchodilator responsiveness during their stay in our pulmonary rehabilitation clinic.</p><p><strong>Results: </strong>Prior to bronchial dilation, 6 out of 134 patients (4.47%) presented an FEV1/FVC ratio below lower limit of normal (Z-score = -1.645) indicative of an obstructive airway disease. Following inhalation of a β2-adrenergic agonist we measured a mean FEV1 increase of 181.5 mL in our cohort, which was significantly elevated compared to a historical control group (ΔFEV1 = 118 mL). 28.7% of the patients showed an increase greater than 200 mL and 12% displayed a significant bronchodilation response (&gt;200 mL ΔFEV1 and &gt;12% FEV1 increase). Interestingly, no significant difference in bronchial dilation effect was observed when comparing patients hospitalized and those non-hospitalized during the course of their SARS-CoV-2 infection.</p><p><strong>Conclusion: </strong>Our data provide evidence for increased prevalence of obstructive ventilatory defects and increased bronchodilator responsiveness in patients with persisting symptoms after COVID-19. Depending on the extent of this complication, post-COVID patients may benefit from an adapted β2-inhalation therapy including subsequent reevaluation.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"622-629"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Endobronchial Valve Placement in the Treatment of Persistent Bronchopleural Fistula and Empyema Allows the Avoidance of Right Completion Pneumonectomy. 在治疗顽固性支气管胸膜瘘和肺水肿时,成功植入支气管内瓣膜可避免右肺完全切除术。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-10-24 DOI: 10.1159/000542018
Didier Lardinois, Kathleen Jahn, Aljaz Hojski, Spasenija Savic Prince, Nikolay Tsvetkov, Zeljko Djakovic, Helga Bachmann, Michael Tamm

Introduction: This case report addresses the complexity of management of air leak and persisting infection in polymorbid patients.

Case presentation: A 56-year-old former marble mason presented with major hemoptysis. Chest CT revealed severe silicosis and pneumonia with an abscess in the right lower lobe and a pulmonary artery pseudoaneurysm. An open lower bilobectomy with empyema debridement was performed, and the posterior upper lobe segment was covered with a serratus anterior muscle flap. The second examination revealed persistent air leakage from the infected posterior upper lobe segment and necrosis of the muscle flap. Atypical resection of this segment was performed, and the surface of the lower part of the remnant lung was covered with a fat flap and then the omentum. The patient was discharged but was readmitted 2 weeks later due to empyema. During reoperation, a persistent infection in the remnant posterior upper lobe segment was observed in addition to a bronchopleural fistula. The only possible surgery that would cure the patient was right completion pneumonectomy. To avoid this high-risk operation, an endobronchial valve was placed intraoperatively in the posterior segment bronchus, leading to closure of the fistula and resolution of the infection. The patient recovered well and was discharged 10 days later. At the 1-year follow-up, the patient was free of symptoms and reported a good quality of life.

Conclusion: This case is an excellent example of successful cooperation between an interventional pulmonologist and a thoracic surgeon to avoid right pneumonectomy in a polymorbid patient.

导言:本病例报告探讨了多病患者漏气和持续感染管理的复杂性:本病例报告探讨了多病患者漏气和持续感染处理的复杂性:一名 56 岁的前大理石砌筑工因大咯血前来就诊。胸部 CT 显示患者患有严重的矽肺和肺炎,右下叶有脓肿和肺动脉假性动脉瘤。患者接受了开放性双下叶切除术,并清除了肺水肿,上叶后段用前锯肌皮瓣覆盖。第二次检查发现,受感染的后上叶段持续漏气,肌瓣坏死。于是对该部分进行了非典型切除,并用脂肪瓣和网膜覆盖残肺下部表面。患者痊愈出院,但两周后因肺水肿再次入院。再次手术时,除了支气管胸膜瘘外,还发现残余上叶后段有持续感染。唯一可能治愈患者的手术是右肺完全切除术。为了避免这种高风险手术,术中在后段支气管内放置了一个支气管内瓣膜,从而关闭了瘘管并消除了感染。患者恢复良好,10 天后出院。随访一年后,患者症状消失,生活质量良好:本病例是介入肺科医生和胸外科医生成功合作的典范,避免了对多发病患者进行右肺切除术。
{"title":"Successful Endobronchial Valve Placement in the Treatment of Persistent Bronchopleural Fistula and Empyema Allows the Avoidance of Right Completion Pneumonectomy.","authors":"Didier Lardinois, Kathleen Jahn, Aljaz Hojski, Spasenija Savic Prince, Nikolay Tsvetkov, Zeljko Djakovic, Helga Bachmann, Michael Tamm","doi":"10.1159/000542018","DOIUrl":"10.1159/000542018","url":null,"abstract":"<p><strong>Introduction: </strong>This case report addresses the complexity of management of air leak and persisting infection in polymorbid patients.</p><p><strong>Case presentation: </strong>A 56-year-old former marble mason presented with major hemoptysis. Chest CT revealed severe silicosis and pneumonia with an abscess in the right lower lobe and a pulmonary artery pseudoaneurysm. An open lower bilobectomy with empyema debridement was performed, and the posterior upper lobe segment was covered with a serratus anterior muscle flap. The second examination revealed persistent air leakage from the infected posterior upper lobe segment and necrosis of the muscle flap. Atypical resection of this segment was performed, and the surface of the lower part of the remnant lung was covered with a fat flap and then the omentum. The patient was discharged but was readmitted 2 weeks later due to empyema. During reoperation, a persistent infection in the remnant posterior upper lobe segment was observed in addition to a bronchopleural fistula. The only possible surgery that would cure the patient was right completion pneumonectomy. To avoid this high-risk operation, an endobronchial valve was placed intraoperatively in the posterior segment bronchus, leading to closure of the fistula and resolution of the infection. The patient recovered well and was discharged 10 days later. At the 1-year follow-up, the patient was free of symptoms and reported a good quality of life.</p><p><strong>Conclusion: </strong>This case is an excellent example of successful cooperation between an interventional pulmonologist and a thoracic surgeon to avoid right pneumonectomy in a polymorbid patient.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"777-781"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deventilation Syndrome in COPD Patients Receiving Long-Term Home Noninvasive Ventilation: A Systematic Scoping Review. 长期接受家庭无创通气治疗的 COPD 患者的脱气综合征:系统性范围审查。
IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1159/000535704
Maximilian Wollsching-Strobel, Karsten Stannek, Daniel Sebastian Majorski, Friederike Sophie Magnet, Doreen Kroppen, Melanie Patricia Berger, Maximilian Zimmermann, Wolfram Windisch, Sarah Bettina Stanzel

The treatment of patients with COPD and chronic hypercapnic respiratory failure using noninvasive ventilation (NIV) is well established. A "deventilation syndrome" (DVS) has been described as acute dyspnea after cessation of NIV therapy. A systematic scoping review reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) searching Embase was conducted in September 2021. A final manual search followed in February 2023. Literature synthesis was blinded using Rayyan by three different reviewers. A total of 2,009 studies were screened. Five studies met the eligibility criteria. Four articles presented original data. Three articles examined potential treatment options. Three studies were prospective; none were randomized. A total of 122 patients were included. DVS was defined differently in all studies. Seventy-four patients were identified to suffer from DVS (48 controls). Patients were evaluated by blood gas analysis, transcutaneous TcCO2 measurement, spirometry, whole-body plethysmography, respiratory muscle assessments, diaphragmatic electromyography, ultrasound, 6-min walk test, polysomnography, and questionnaires. Treatment approaches studied were minimization of "patient-ventilator asynchrony" (PVA) and use of pursed- lip breathing ventilation. Pathophysiological mechanisms discussed were PVA, high inspiratory positive airway pressure, hyperinflation, respiratory muscle impairment, and increased respiratory rates. Compared with controls, patients with DVS appeared to suffer from more severe airway obstruction, hyperinflation, and PaCO2 retention; worse exercise test scores; and poorer quality of life. The available evidence does not allow for definite conclusions about pathophysiological mechanisms, ethology, or therapeutic options. Future studies should focus on a consistent definition and possible pathomechanisms.

使用无创通气(NIV)治疗慢性阻塞性肺病和慢性高碳酸血症呼吸衰竭患者的方法已得到广泛认可。脱气综合征"(DVS)被描述为停止 NIV 治疗后出现的急性呼吸困难。2021 年 9 月,根据《系统综述和荟萃分析的首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews,PRISMA-ScR),对 Embase 进行了系统的范围界定综述检索。随后于 2023 年 2 月进行了最后一次人工检索。文献综述由三位不同的审稿人使用 Rayyan 进行盲法处理。共筛选出 2,009 项研究。五项研究符合资格标准。四篇文章提供了原始数据。三篇文章研究了潜在的治疗方案。三项研究为前瞻性研究,均未采用随机方法。共纳入 122 名患者。所有研究对 DVS 的定义各不相同。74 名患者被确认患有 DVS(48 名对照组患者)。对患者的评估包括血气分析、经皮 TcCO2 测量、肺活量测定、全身胸透、呼吸肌评估、膈肌电图、超声波、6 分钟步行测试、多导睡眠图和问卷调查。研究的治疗方法包括尽量减少 "患者-呼吸机不同步"(PVA)和使用抿唇呼吸通气。讨论的病理生理机制包括 PVA、高吸气气道正压、过度充气、呼吸肌损伤和呼吸频率增加。与对照组相比,DVS 患者似乎患有更严重的气道阻塞、过度充气和 PaCO2 滞留;运动测试评分更差;生活质量更差。现有证据无法对病理生理机制、伦理学或治疗方案做出明确结论。未来的研究应侧重于一致的定义和可能的病理机制。
{"title":"Deventilation Syndrome in COPD Patients Receiving Long-Term Home Noninvasive Ventilation: A Systematic Scoping Review.","authors":"Maximilian Wollsching-Strobel, Karsten Stannek, Daniel Sebastian Majorski, Friederike Sophie Magnet, Doreen Kroppen, Melanie Patricia Berger, Maximilian Zimmermann, Wolfram Windisch, Sarah Bettina Stanzel","doi":"10.1159/000535704","DOIUrl":"10.1159/000535704","url":null,"abstract":"<p><p>The treatment of patients with COPD and chronic hypercapnic respiratory failure using noninvasive ventilation (NIV) is well established. A \"deventilation syndrome\" (DVS) has been described as acute dyspnea after cessation of NIV therapy. A systematic scoping review reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) searching Embase was conducted in September 2021. A final manual search followed in February 2023. Literature synthesis was blinded using Rayyan by three different reviewers. A total of 2,009 studies were screened. Five studies met the eligibility criteria. Four articles presented original data. Three articles examined potential treatment options. Three studies were prospective; none were randomized. A total of 122 patients were included. DVS was defined differently in all studies. Seventy-four patients were identified to suffer from DVS (48 controls). Patients were evaluated by blood gas analysis, transcutaneous TcCO2 measurement, spirometry, whole-body plethysmography, respiratory muscle assessments, diaphragmatic electromyography, ultrasound, 6-min walk test, polysomnography, and questionnaires. Treatment approaches studied were minimization of \"patient-ventilator asynchrony\" (PVA) and use of pursed- lip breathing ventilation. Pathophysiological mechanisms discussed were PVA, high inspiratory positive airway pressure, hyperinflation, respiratory muscle impairment, and increased respiratory rates. Compared with controls, patients with DVS appeared to suffer from more severe airway obstruction, hyperinflation, and PaCO2 retention; worse exercise test scores; and poorer quality of life. The available evidence does not allow for definite conclusions about pathophysiological mechanisms, ethology, or therapeutic options. Future studies should focus on a consistent definition and possible pathomechanisms.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"60-69"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Respiration
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1